Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic AdMSCs for COVID-19
NCT04428801Phase 2Not yet recruiting
- Sponsor
- Celltex Therapeutics
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of autologous adipose-derived stem cells in coronavirus disease 2019 (COVID-19), sponsored by Celltex Therapeutics. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
autologous adipose-derived stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04428801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428801.